Serum vitamin D and hippocampal gray matter volume in schizophrenia

Psychiatry Research - Neuroimaging

Volumn 233, Issue 2, 2015, Pages 175-179

  Shivakumar, Venkataram ^a   Kalmady, Sunil V ^a   Amaresha, Anekal C ^a   Jose, Dania ^a   Narayanaswamy, Janardhanan C ^a   Agarwal, Sri Mahavir ^a   Joseph, Boban ^a   Venkatasubramanian, Ganesan ^a   Ravi, Vasanthapuram ^a   Keshavan, Matcheri S ^b   Gangadhar, Bangalore N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hippocampus; Schizophrenia; Vitamin D

Indexed keywords

VITAMIN D; CALCITRIOL RECEPTOR;

ADULT; AGE; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; IMMUNOASSAY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SCHIZOPHRENIA; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VOXEL BASED MORPHOMETRY; BLOOD; COMPLICATION; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; STATISTICS;

ADULT; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; RECEPTORS, CALCITRIOL; RISK FACTORS; SCHIZOPHRENIA; STATISTICS AS TOPIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84938747553     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2015.06.006     Document Type: Article

References (49)

1. Andersen R., Brot C., Jakobsen J., Mejborn H., Molgaard C., Skovgaard L.T., Trolle E., Tetens I., Ovesen L. Seasonal changes in vitamin D status among Danish adolescent girls and elderly women: the influence of sun exposure and vitamin D intake. Eur. J. Clin. Nutr. 2013, 67:270-274.
2. Andreasen N. The Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City.
3. Andreasen N. The Scale for the Assessment of Positive Symptoms 1984, University of Iowa, Iowa City.
4. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
5. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
6. Belvederi Murri M., Respino M., Masotti M., Innamorati M., Mondelli V., Pariante C., Amore M. Vitamin D and psychosis: mini meta-analysis. Schizophr. Res. 2013, 150:235-239.
7. Brett, M., Anton, J.-L., Valabregue, R., Poline, J.-B., 2002. Region of interest analysis using an SPM toolbox. Presented at the 8th International Conference on Functional Mapping of the Human Brain. NeuroImage, pp. 16.
8. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007, 94:1-11.
9. Clelland J.D., Read L.L., Drouet V., Kaon A., Kelly A., Duff K.E., Nadrich R.H., Rajparia A., Clelland C.L. Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of association. Schizophrenia Research 2014, 156(1):15-22.
10. Cohen S.M., Nadler J.V. Proline-induced inhibition of glutamate release in hippocampal area CA1. Brain Res. 1997, 769:333-339.
11. Erickson K.I., Prakash R.S., Voss M.W., Chaddock L., Heo S., McLaren M., Pence B.D., Martin S.A., Vieira V.J., Woods J.A., McAuley E., Kramer A.F. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J. Neurosci. 2010, 30:5368-5375.
12. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D3 and brain development. Neuroscience 2003, 118:641-653.
13. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29:21-30.
14. Garcion E., Nataf S., Berod A., Darcy F., Brachet P. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol. Brain Res. 1997, 45:255-267.
15. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 2002, 13:100-105.
16. Graham K.A., Keefe R.S., Lieberman J.A., Calikoglu A.S., Lansing K.M., Perkins D.O. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv. Psychiatry 2014, 10.1111/eip.12122 (online).
17. Harinarayan C.V., Ramalakshmi T., Prasad U.V., Sudhakar D. Vitamin D status in Andhra Pradesh: a population based study. Indian J. Med. Res. 2008, 127:211-218.
18. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 2004, 174:151-162.
19. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Curr. Top. Behav. Eurosci. 2010, 4:529-553.
20. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:1911-1930.
21. Humble M.B., Gustafsson S., Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J. Steroid Biochem. Mol. Biol. 2010, 121:467-470.
22. Itzhaky D., Amital D., Gorden K., Bogomolni A., Arnson Y., Amital H. Low serum vitamin D concentrations in patients with schizophrenia. Israel Med. Assoc. J. 2012, 14:88-92.
23. Kalmady S.V., Venkatasubramanian G., Shivakumar V., Gautham S., Subramaniam A., Jose D.A., Maitra A., Ravi V., Gangadhar B.N. Relationship between Interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility?. PLoS One 2014, 9:e96021.
24. Kalmady S.V., Venkatasubramanian G., Shivakumar V., Jose D., Ravi V., Gangadhar B.N. Relationship between brain-derived neurotrophic factor and Schneiderian first rank symptoms in antipsychotic-naive schizophrenia. Front. Psychiatry 2013, 4:64.
25. Kalueff A.V., Minasyan A., Keisala T., Kuuslahti M., Miettinen S., Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol. Disord. Drug Targets 2006, 5:363-371.
26. Karayiorgou M., Gogos J.A. The molecular genetics of the 22q11-associated schizophrenia. Mol. Brain Res. 2004, 132:95-104.
27. Kiraly S.J., Kiraly M.A., Hawe R.D., Makhani N. Vitamin D as a neuroactive substance: review. Sci. World J. 2006, 6:125-139.
28. Landfield P.W., Cadwallader-Neal L. Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol. Aging 1998, 19:469-477.
29. Langub M.C., Herman J.P., Malluche H.H., Koszewski N.J. Evidence of functional vitamin D receptors in rat hippocampus. Neuroscience 2001, 104:49-56.
30. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
31. McCann J.C., Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J. 2008, 22:982-1001.
32. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R., Chant D., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 2004, 67:237-245.
33. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., Norgaard-Pedersen B., Hougaard D.M., Mortensen P.B. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch. Gen. Psychiatry 2010, 67:889-894.
34. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
35. Mithal A., Wahl D.A., Bonjour J.P., Burckhardt P., Dawson-Hughes B., Eisman J.A., El-Hajj Fuleihan G., Josse R.G., Lips P., Morales-Torres J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 2009, 20:1807-1820.
36. Naveilhan P., Neveu I., Baudet C., Funakoshi H., Wion D., Brachet P., Metsis M. 1,25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. Mol. Brain Res. 1996, 41:259-268.
37. Naveilhan P., Neveu I., Wion D., Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 1996, 7:2171-2175.
38. Phang J.M., Liu W., Zabirnyk O. Proline metabolism and microenvironmental stress. Annu. Rev. Nutr. 2010, 30:441-463.
39. Rey-Sanchez P., Lavado-Garcia J.M., Canal-Macias M.L., Gomez-Zubeldia M.A., Roncero-Martin R., Pedrera-Zamorano J.D. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum. Psychopharmacol. 2009, 24:49-54.
40. Samuelsson A.M., Jennische E., Hansson H.A., Holmang A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am. J. Physiol. Regul., Integr. Comp. Physiol. 2006, 290:R1345-R1356.
41. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-23. (quiz 34-57).
42. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J.f Psychiatry 2006, 188:510-518.
43. Suntsova M., Gogvadze E.V., Salozhin S., Gaifullin N., Eroshkin F., Dmitriev S.E., Martynova N., Kulikov K., Malakhova G., Tukhbatova G., Bolshakov A.P., Ghilarov D., Garazha A., Aliper A., Cantor C.R., Solokhin Y., Roumiantsev S., Balaban P., Zhavoronkov A., Buzdin A. Human-specific endogenous retroviral insert serves as an enhancer for the schizophrenia-linked gene PRODH. Proc. Natl. Acad. Sci. USA 2013, 110:19472-19477.
44. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
45. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001, 904:67-75.
46. Wang X., Michaelis E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2010, 2:12.
47. Willis A., Bender H.U., Steel G., Valle D. PRODH variants and risk for schizophrenia. Amino Acids 2008, 35:673-679.
48. Wion D., MacGrogan D., Neveu I., Jehan F., Houlgatte R., Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 1991, 28:110-114.
49. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2013, 46:200-206.